Dawson James Reiterates First Wave BioPharma (FWBI) at Neutral, Puts MS1819 Probability of Success at 10%, Sees no Synergies With the Acquired Niclosamide
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Neutral rating on First Wave BioPharma, Inc. (NASDAQ: FWBI), following the company's announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
